SubsidieMeestersNon-ionizing Metabolic Imaging for predicting the effect of and guiding Therapeutic Interventions
MITI aims to develop advanced non-invasive metabolic imaging technology for early disease detection and therapy effectiveness assessment, improving patient outcomes and reducing healthcare costs.
Projectdetails
Introduction
MITI will develop and mature a novel, ground-breaking technology for high precision non-ionizing metabolic imaging, enabling fast and non-invasive detection of the markers of metabolic processes e.g., cell proliferation and energy metabolism.
Impact on Healthcare
Using the results of metabolic imaging, medical specialists will be able to establish the effectiveness of therapies and determine the specific disease months sooner than is possible with currently available technologies. This will increase patient well-being and reduce the costs of healthcare as unsuccessful therapies can be stopped and replaced earlier by more effective (personalised) therapies.
Market Potential
This solution addresses an enormous market with millions of patients worldwide. MITI builds on the results of NICI in which the basic key marker molecules for metabolic imaging on MRI platforms were successfully discovered (1H, 2H, 31P and 23Na), including the capability to detect these by inserts on 7T MRI platforms.
Project Components
MITI comprises:
- The further development and testing of a basic double tuned metabolic imaging set (detecting 1H and one of the following molecules: 2H or 31P or 23Na).
- Validation of the basic technology to detect metabolic markers in specific use cases:
- Cell proliferation metabolism after treatment of lung tumours and pancreatic cancer with liver metastases.
- Cardiac drug mechanisms.
- Energy metabolism of muscle dystrophy.
- Development of an advanced quadruple tuned metabolic imaging set that will broaden the spectrum of metabolic processes that can be successfully viewed in parallel.
Future Plans
The results of the use cases will be used for power calculations for clinical trials to be conducted after MITI. The MITI partners aim to commercialize the technology, directly after MITI by providing it to clinicians in research centres and within 3 years after MITI to general medical centres.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.100.238 |
| Totale projectbegroting | € 2.100.238 |
Tijdlijn
| Startdatum | 1-4-2022 |
| Einddatum | 30-9-2025 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- UNIVERSITAIR MEDISCH CENTRUM UTRECHTpenvoerder
- TESLA DYNAMIC COILS BV
- Fondazione Stella Maris
- UNIVERSITAETSKLINIKUM ESSEN
- THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE
Land(en)
Vergelijkbare projecten binnen EIC Transition
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Targeting cardiac fibrosis with next generation RNA therapeuticsFIBREX aims to develop an innovative ncRNA-based antisense oligonucleotide therapy targeting Meg3 to reverse cardiac fibrosis and treat heart failure, advancing towards clinical readiness. | EIC Transition | € 2.499.482 | 2022 | Details |
automated in-line separatioN and dEtection of eXtracellular vesicles for liqUid biopsy applicationSThe NEXUS project aims to industrialize a customizable platform for the separation and analysis of extracellular vesicles from biofluids, enhancing cancer diagnostics and monitoring. | EIC Transition | € 2.497.750 | 2022 | Details |
Predictive REagent-Antibody Replacement Technology stage 2-TranslationPRe-ART-2T aims to advance predictive antibody technology to TRL6, replacing low-quality monoclonal antibodies with high-performing synthetic alternatives, and attract ~€20M in investment. | EIC Transition | € 800.000 | 2022 | Details |
Advancing a vaccine targeting genetic amyotrophic lateral sclerosis (C9orf72 ALS) to the clinical stageDeveloping a poly-GA peptide vaccine to reduce protein aggregation and motor deficits in C9orf72 ALS, aiming for clinical evaluation and market entry through strategic partnerships. | EIC Transition | € 2.499.810 | 2022 | Details |
Targeting cardiac fibrosis with next generation RNA therapeutics
FIBREX aims to develop an innovative ncRNA-based antisense oligonucleotide therapy targeting Meg3 to reverse cardiac fibrosis and treat heart failure, advancing towards clinical readiness.
automated in-line separatioN and dEtection of eXtracellular vesicles for liqUid biopsy applicationS
The NEXUS project aims to industrialize a customizable platform for the separation and analysis of extracellular vesicles from biofluids, enhancing cancer diagnostics and monitoring.
Predictive REagent-Antibody Replacement Technology stage 2-Translation
PRe-ART-2T aims to advance predictive antibody technology to TRL6, replacing low-quality monoclonal antibodies with high-performing synthetic alternatives, and attract ~€20M in investment.
Advancing a vaccine targeting genetic amyotrophic lateral sclerosis (C9orf72 ALS) to the clinical stage
Developing a poly-GA peptide vaccine to reduce protein aggregation and motor deficits in C9orf72 ALS, aiming for clinical evaluation and market entry through strategic partnerships.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Deuterium labeling of GLUCOse improves magnetic resonance imaging Sensitivity to CANcer metabolismGLUCO-SCAN aims to develop and clinically evaluate a novel whole-body deuterium metabolic imaging (DMI) method for cancer assessment, overcoming PET's limitations and enabling widespread screening. | ERC COG | € 2.495.924 | 2023 | Details |
REAL TIME MOLECULAR IMAGER WITH UNSURPASSED RESOLUTIONRETIMAGER aims to revolutionize PET imaging by achieving ten-fold improvements in spatial and temporal resolution, enabling real-time, high-sensitivity imaging for personalized precision medicine. | EIC Pathfinder | € 3.126.347 | 2023 | Details |
Transformative Pediatric Brain Cancer Imaging using Integrated Biophysics-AI Molecular MRIDevelop a novel AI-driven molecular MRI technology for rapid, noninvasive monitoring of pediatric brain cancer treatment response, enhancing precision medicine and understanding of tumor dynamics. | ERC STG | € 1.497.669 | 2024 | Details |
Hyperpolarized Magnetic Resonance at the point-of-careHYPMET aims to revolutionize personalized cancer treatment by developing a compact NMR technology for real-time monitoring of metabolic pathways and body fluid analyses using enhanced hyperpolarization methods. | ERC STG | € 1.499.968 | 2024 | Details |
Deuterium labeling of GLUCOse improves magnetic resonance imaging Sensitivity to CANcer metabolism
GLUCO-SCAN aims to develop and clinically evaluate a novel whole-body deuterium metabolic imaging (DMI) method for cancer assessment, overcoming PET's limitations and enabling widespread screening.
REAL TIME MOLECULAR IMAGER WITH UNSURPASSED RESOLUTION
RETIMAGER aims to revolutionize PET imaging by achieving ten-fold improvements in spatial and temporal resolution, enabling real-time, high-sensitivity imaging for personalized precision medicine.
Transformative Pediatric Brain Cancer Imaging using Integrated Biophysics-AI Molecular MRI
Develop a novel AI-driven molecular MRI technology for rapid, noninvasive monitoring of pediatric brain cancer treatment response, enhancing precision medicine and understanding of tumor dynamics.
Hyperpolarized Magnetic Resonance at the point-of-care
HYPMET aims to revolutionize personalized cancer treatment by developing a compact NMR technology for real-time monitoring of metabolic pathways and body fluid analyses using enhanced hyperpolarization methods.